Ionis Brings Treatment for Gastrointestinal Immune Disorders to Clinical-trial Stage

Ionis Brings Treatment for Gastrointestinal Immune Disorders to Clinical-trial Stage
Janssen Biotech plans a Phase 1 clinical trial of a therapy that its partner Ionis Pharmaceuticals developed as a treatment for gastrointestinal immune disorders. Under their collaboration agreement, Ionis received $5 million for bringing the therapy, IONIS-JBI 1-2.5 Rx, to the clinical-trial stage. Janssen is responsible for obtaining regulatory approval of the treatment worldwide, and commercializing it. Ionis stands to gain up to $585 million more in milestone payments and license fees. It will also receive a percentage of the sales of any product that reaches the market. Ionis specializes in RNA-focused therapies for patients with unmet medical needs, including those with gastrointestinal immune disorders and inflammatory bowel diseases. Ionis used its proprietary antisense technology to develop IONIS-JBI 1-2.5 Rx. An antisense therapy consists of snythetic RNA that binds to the messenger RNA a faulty gene produces. The binding inactivates the messenger RNA, turning the gene off. This silencing prevents the gene from producing the abnormal protein associated with a disease. IONIS-JBI 1-2.5 Rx is the first oral antisense therapy for gastrointestinal immune disorders that Ionis has brought to the clinical-trial stage. "We are pleased with the success of our collaboration with Janssen," C. Frank Bennett, Ionis' senior vice president of research, said in a
Subscribe or to access all post and page content.